{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:26:12Z","timestamp":1792844772496,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.anndiagpath.2019.151449","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:55:56Z","timestamp":1576612556000},"page":"151449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms"],"prefix":"10.1016","volume":"44","author":[{"given":"Gabriel K.","family":"Habermehl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan O.","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu V.","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anndiagpath.2019.151449_bb0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992\u20132004","volume":"144","author":"Dores","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.anndiagpath.2019.151449_bb0010","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.anndiagpath.2019.151449_bb0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"38","author":"van de Donk","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2019.151449_bb0020","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.anndiagpath.2019.151449_bb0025","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1158\/1078-0432.CCR-08-3150","article-title":"Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.anndiagpath.2019.151449_bb0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2016.10.026","article-title":"The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits","volume":"91","author":"Vignon","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.151449_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2008.07423.x","article-title":"Long-term follow-up of a population based cohort with monoclonal proteinaemia","volume":"144","author":"Schaar","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2019.151449_bb0040","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1309\/AJCP0N7IELYUNJGZ","article-title":"IgM multiple myeloma: pathologic evaluation of a rare entity","volume":"140","author":"King","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2019.151449_bb0045","first-page":"798","article-title":"Unusual myelomas: a review of IgD and IgE variants","volume":"27","author":"Pandey","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"10.1016\/j.anndiagpath.2019.151449_bb0050","first-page":"803","article-title":"IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities","volume":"27","author":"Richardson","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"10.1016\/j.anndiagpath.2019.151449_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCO.0000000000000331","article-title":"Utility of flow cytometry studies in the management of patients with multiple myeloma","volume":"28","author":"Paiva","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.151449_bb0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1309\/AJCPC7RWYPYG8UGY","article-title":"A challenging diagnosis: crystal-storing histiocytosis in plasma cell myeloma","volume":"143","author":"Lee","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2019.151449_bb0065","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2006-03-008953","article-title":"Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials","volume":"108","author":"Drayson","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.anndiagpath.2019.151449_bb0070","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1002\/cncr.28946","article-title":"IgA kappa\/IgA lambda heavy\/light chain assessment in the management of patients with IgA myeloma","volume":"120","author":"Boyle","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.151449_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1373\/clinchem.2014.234757","article-title":"Heavy\/light chain assay for monitoring IgA multiple myeloma: digging out the IgA from the beta region","volume":"61","author":"Calderon","year":"2015","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.151449_bb0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2014.231985","article-title":"Monitoring IgA multiple myeloma: immunoglobulin heavy\/light chain assays","volume":"61","author":"Katzmann","year":"2015","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.anndiagpath.2019.151449_bb0085","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom\u2019s macroglobulinemia","volume":"27","author":"Jimenez","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.anndiagpath.2019.151449_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3324\/haematol.2013.092817","article-title":"Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Thiago","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.anndiagpath.2019.151449_bb0095","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clml.2011.06.014","article-title":"Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen","volume":"11","author":"Szturz","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.anndiagpath.2019.151449_bb0100","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.151449_bb0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-011-1293-1","article-title":"Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany","volume":"91","author":"Eisele","year":"2012","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2019.151449_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.anndiagpath.2019.151449_bb0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41379-018-0011-0","article-title":"Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms","volume":"31","author":"Gao","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2019.151449_bb0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.humpath.2018.09.008","article-title":"IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases","volume":"84","author":"Angelova","year":"2019","journal-title":"Hum Pathol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913419303788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913419303788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:31:45Z","timestamp":1761078705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913419303788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"alternative-id":["S1092913419303788"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.151449","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.151449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151449"}}